High terminal creatinine donors should not preclude simultaneous kidney and pancreas transplantation

Am J Surg. 2021 Apr;221(4):677-680. doi: 10.1016/j.amjsurg.2020.09.031. Epub 2020 Sep 28.

Abstract

Background: Simultaneous pancreas and kidney transplantation (SPK) in the setting of end-stage renal disease offers unmatched outcomes in insulin dependent diabetic patients. Donor pool expansion through the transplantation of kidneys with acute kidney injury (AKI) is controversial.

Methods: 59 SPK transplants were classified by presence of donor AKI, defined as donor terminal creatinine ≥ 1.5x the initial creatinine or donor terminal creatinine > 4.0 mg/dL. Endpoints included graft and patient survival, delayed graft function (DGF), serum creatinine, glomerular filtration rate (GFR), Hemoglobin A1c (HbA1c) and acute rejection.

Results: The donor AKI group (n = 35) had significantly higher rates of DGF (38 v. 9%, p = 0.01). There was no difference in creatinine or GFR at 1, 3, 6 and 12 months. HbA1c was comparable at 3, 6 and 12 months. There was no significant difference in the percentage of patients that required anti-diabetic agents after transplant (14 v. 4%, p = 0.56).

Conclusions: We observed increased rates of DGF in SPK recipients with donor AKI. However, equivalent outcomes of pancreas and kidney function in both groups were observed.

Keywords: Delayed graft function; Donor acute kidney injury; Graft function; Simultaneous pancreas kidney transplantation.

MeSH terms

  • Adult
  • Biomarkers / blood
  • Creatinine / blood*
  • Diabetes Mellitus / surgery*
  • Donor Selection*
  • Female
  • Glomerular Filtration Rate
  • Graft Rejection
  • Graft Survival
  • Humans
  • Kidney Failure, Chronic / blood*
  • Kidney Failure, Chronic / surgery*
  • Kidney Transplantation*
  • Male
  • Pancreas Transplantation*
  • Retrospective Studies

Substances

  • Biomarkers
  • Creatinine